Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease

Pediatric Blood and Cancer

Volumn 55, Issue 7, 2010, Pages 1338-1342

  Kalpatthi, Ram ^a   Peters, Brittany ^a   Kane, Ian ^a   Holloman, David ^a   Rackoff, Elizabeth ^a   Disco, Deborah ^a   Jackson, Sherron ^a   Laver, Joseph H ^b   Abboud, Miguel R ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Chelation; Desferrioxamine; Hemoglobinopathy; High dose; Iron overload

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEFEROXAMINE; LIVER ENZYME;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FERRITIN BLOOD LEVEL; HISTOLOGY; HUMAN; HUMAN TISSUE; IRON OVERLOAD; IRON STORAGE; LIVER BIOPSY; LIVER FUNCTION; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANEMIA, SICKLE CELL; ASPARTATE AMINOTRANSFERASES; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; DEFEROXAMINE; FEMALE; FERRITINS; HUMANS; INFUSIONS, INTRAVENOUS; IRON OVERLOAD; LIVER; MALE; SIDEROPHORES; YOUNG ADULT;

EID: 78049251987     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22660     Document Type: Article

References (28)

1. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995; 126: 896-899.
2. Wang WC, Kovnar EH, Tonkin IL, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 1991; 118: 377-382.
3. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review. Transfusion 2007; 47: 1919-1929.
4. Cohen AR, Mizanin J, Schwartz E. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J Pediatr 1989; 115: 151-155.
5. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992; 79: 2741-2748.
6. Levine JE, Cohen A, MacQueen M, et al. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment. J Pediatr Hematol Oncol 1997; 19: 139-141.
7. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95: 1229-1236.
8. Wali YA, Taqi A, Deghaidi A. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections. Pediatr Hematol Oncol 2004; 21: 453-460.
9. Laws HJ, Gobel U, Christaras A, et al. Intensification of chelating-therapy in patients with thalassemia major. Klin Padiatr 2005; 217: 120-125.
10. Nelson SC, Hennessy JM, McDonough EA, et al. Weekend very high-dose intravenous deferoxamine in children with transfusional iron overload. J Pediatr Hematol Oncol 2006; 28: 182-185.
11. Freedman MH, Grisaru D, Olivieri N, et al. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. Am J Dis Child 1990; 144: 565-569.
12. Porter JB, Jaswon MS, Huehns ER, et al. Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989; 73: 403-409.
13. Chiodo AA, Alberti PW, Sher GD, et al. Desferrioxamine ototoxicity in an adult transfusion-dependent population. J Otolaryngol 1997; 26: 116-122.
14. Searle J, Leggett BA, Crawford DH, et al. Iron storage diseases. In: MacSween RN, Burt A, Portmann B, Ishak K, Scheur P, Anthony P, editors. Pathology of the liver, 4th edition. London: Churchill Livingstone; 2002. pp. 252-272.
15. Karam LB, Disco D, Jackson SM. et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions poor correlation with ferritin levels. Pediatr Blood Cancer 2008; 50: 62-65.
16. Cohen A, Schwartz E. Iron chelation therapy with deferoxamine in Cooley anemia. J Pediatr 1978; 92: 643-647.
17. Silliman CC, Peterson VM, Mellman DL, et al. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: A randomized, double-blind study of the dose-response relationship. J Lab Clin Med 1993; 122: 48-54.
18. Graziano JH, Markenson A, Miller DR, et al. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine. J Pediatr 1978; 92: 648-652.
19. Koren G, Bentur Y, Strong D, et al. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1989; 143: 1077-1080.
20. Kim HC, Dugan NP, Silber JH, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 1994; 83: 1136-1142.
21. Cappellini MD. Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag 2007; 3: 291-299.
22. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007; 29: 909-917.
23. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematol 2008; 119: 133-141.
24. Raphael JL, Bernhardt MB, Mahoney DH, et al. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatr Blood Cancer 2009; 52: 616-620.
25. Otto-Duessel M, Brewer C, Gonzalez I, et al. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol 2008; 120: 123-128.
26. Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. Comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin 2006; 30: 329-347.
27. Porter JB, Abeysinghe RD, Marshall L, et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996; 88: 705-713.
28. Link G, Pinson A, Hershko C. Heart cells in culture: A model of myocardial iron overload and chelation. J Lab Clin Med 1985; 106: 147-153.